Advertisement


Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

2024 ASCO Annual Meeting

Advertisement

Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Saci-IO HR+ was a randomized phase II investigator-initiated study to evaluate the efficacy of the trop2 directed antibody drug conjugate sacituzumab govitecan with or without the PD-1 inhibitor pembrolizumab in patients with metastatic hormone receptor-positive HER2 negative breast cancer. SG, sacituzumab govitecan, has demonstrated to improve median progression free and overall survival in patients with previously treated hormone receptor positive HER2 negative breast cancer who have received two to four prior chemotherapies for advanced disease as shown in the TROPiCS-02 study. We know that the payload of sacituzumab govitecan SN38 can enhance cytotoxic T-cell effector functions and deplete regulatory T-cells. It can also stimulate the cGAS-STING pathway increasing T-cell infiltration into the tumor, and thus we hypothesized that the combination of SG plus pembrolizumab would enhance the efficacy of SG alone in metastatic hormone receptor positive HER2 negative breast cancer. Saci-IO HR+ randomized patients one-to-one to receive SG plus pembrolizumab or SG alone in the metastatic hormone receptor positive HER2 negative setting. Patients had to have received prior endocrine therapy for advanced disease or progressed on or within 12 months of adjuvant endocrine therapy and they could have received 0 to 1 prior lines of chemotherapy in the advanced setting. The primary endpoint of the study was progression-free survival in the intent-to-treat population and key secondary endpoints were progression-free survival among patients with PD-L1 positive tumors defined using the 22C3 assay and a combined positive score greater than or equal than 1, and also overall survival in both the intent-to-treat and PD-L1 positive populations. The study demonstrated that the addition of pembrolizumab to sacituzumab govitecan did not significantly improve median progression-free survival in the intent-to-treat population. Median PFS with SG plus pembrolizumab was 8.1 months and median PFS with SG alone was 6.2 month, a hazard ratio of 0.81 and P-value of 0.37. In the intent-to-treat population at a median follow-up of 12.5 months, overall survival did not significantly differ between treatment arms. Median OS with SG plus pembrolizumab was 18.5 months versus 18 months with SG alone. And among patients with PD-L1 positive tumors which comprised about 39% of the patient population defined using the CPS cutoff greater than or equal than 1, there was a 4.4 month absolute difference in median progression-free survival between treatment arms favoring the combination that was not statistically significant. Median PFS with SG plus pembrolizumab was 11.1 months and 6.7 months with SG alone, a hazard ratio of 0.62, P-value of 0.23. Again at a median follow-up of 12.5 months, so overall survival data are not mature, among the patients with PD-L1 positive tumors there was a 6-month numerical increase in median OS with the addition of pembrolizumab to SG. Median OS with the combination was 18.5 months compared to 12.5 months with SG alone. Overall, the safety profile of SG plus pembrolizumab was similar to that reported with either agent and there were no new safety signals that were reported. In conclusion, Saci-IO HR+ is the first randomized trial to evaluate the efficacy of a topoisomerase 1 inhibitor ADC in combination with an immune checkpoint inhibitor in breast cancer. This study did not show a statistically significant difference in median progression free and overall survival among patients with metastatic hormone receptor positive HER2 negative breast cancer who had received up to one prior line of chemotherapy in the advanced setting. Overall survival data are not mature and additional follow-up is needed. Among the patients with PD-L1 positive tumors there was a non-significant 4.4 month numerical increase in median PFS and 6-month increase in median OS with the addition of pembrolizumab to SG, and so we do think that the results from this study support further investigation of the combination of SG plus pembrolizumab in patients with PD-L1 positive metastatic hormone receptor positive, HER2 negative breast cancer.

Related Videos

Lung Cancer

Narjust Florez, MD, and Suresh S. Ramalingam, MD, on EGFR-Mutated NSCLC: Update on Osimertinib and Chemoradiotherapy

Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation therapy improved progression-free survival for patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC), suggesting this agent may represent a new standard of care in this setting (LBA4).

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Breast Cancer

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence, including patients with node-negative disease, and showed a benefit in invasive disease–free survival (Abstract 512).

Prostate Cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Advertisement

Advertisement




Advertisement